Serotonin (5-HT) in brains of adult patients with Down syndrome

Journal of Neural Transmission, Supplement

Volumn , Issue 57, 1999, Pages 221-232

  Seidl, R ^c   Kaehler, S T ^c   Prast, H ^c   Singewald, N ^c   Cairns, N ^a   Gratzer, M ^c   Lubec, G ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; SEROTONIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; OCCIPITAL CORTEX; PATHOGENESIS; PRIORITY JOURNAL; TEMPORAL CORTEX; THALAMUS; BRAIN; METABOLISM; MIDDLE AGED; OCCIPITAL LOBE; PATHOLOGY; REFERENCE VALUE; TEMPORAL LOBE;

ADULT; ALZHEIMER DISEASE; BRAIN; CAUDATE NUCLEUS; CEREBELLUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOWN SYNDROME; FEMALE; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MIDDLE AGED; OCCIPITAL LOBE; REFERENCE VALUES; SEROTONIN; TEMPORAL LOBE; THALAMUS;

EID: 0032585816     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6380-1_14     Document Type: Article

References (46)

1. Andersson A, Sundman I, Marcusson J (1992) Age stability of human brain 5-HT terminals studied with 3H paroxetine binding. Gerontol 38: 127-132
2. Azmitia E, Whitaker-Azmitia P (1991) Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry 52 [Suppl 12]: 4-16
3. Bazelon M, Paine RS, Coeiw VA, Hunt P, Houck JC, Mahanand D (1967) Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan. Lancet i: 1130-1133
4. Becker LE, Mito T, Takashima S, Onodera K (1991) Growth and development of the brain in Down syndrome. Prog Clin Biol Res 373: 133-152
5. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS, Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995) Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 64: 749-760
6. Bowen BB, Francis PT, Chessel IP, Webster MT (1994) Neurotransmission-the link integrating Alzheimer's disease? Trends Neurosci 17: 149-150
7. Casper RC (1998) Serotonin, a major player in regulation of feeding and affect. Biol Psychiatry 44: 795-797
8. Celeda P, Artigas F (1993) Effects of local and systemic MAO inhibitors on extracellular brain 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in the frontal cortex and raphe nuclei of freely moving rats. An in vivo microdialysis study. Naunyn Schmiedebergs Arch Pharmacol 347: 583-590
9. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT (1996) Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 66: 1592-1598
10. Coleman M (1971) Infantile spasms associated with 5-hydroxytryptophan administered in patients with Down's syndrome. Neurol 21: 911
11. Epstein CJ (1995) Down Syndrome (Trisomy 21). In: Scriver SR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 749-794
12. Frazer A, Hensler JG (1999) Serotonin. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds) Basic neurochemistry, molecular, cellular and medical aspects, 6th edn. Lippincott Raven, Philadelphia New York, pp 263-293
13. Gedye A (1990) Dietary increase in serotonin reduces self-injurious behaviour in a Down's syndrome adult. J Ment Defic Res 34: 195
14. Gedye A (1991) Serotonergic treatment for aggression in a Down's syndrome adult showing signs of Alzheimer's disease. J Ment Defic Res 35: 247-258
15. Geldmacher DS, Lerner AJ, Voci JM, Noelker EA, Somple LC, Whitehouse PJ (1997) Treatment of functional decline in adults with Down syndrome using seletive serotonin-reuptake inhibitor drugs. J Geriatr Psychiat Neurol 10: 99-104
16. Godridge H, Reynolds GP, Czudek C, Calcutt NA, Benton M (1987) Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry 50: 775-778
17. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B (1983) Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4: 261-271
18. Haxby JV (1989) Neuropsychological evaluation of adults with Down's syndrome: patterns of selective impairment in nondemented old adults. J Ment Defic Res 33: 193-197
19. Holthoff-Detto K, Kessler J, Herholz K, Bonner H, Pietrzyk U, Wurker M, Ghaemi M, Wienhard K, Wagner R, Heiss WD (1997) Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 54: 145-150
20. Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229
21. Jacobs B, Fornal C (1995) Serotonin and behavior, a general hypothesis. In: Bloom F, Kupfer D (eds) Psychopharmacology: the fourth generation of progess. Raven Press, New York, pp 461-469
22. Lauder JM (1993) Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 16: 233-240
23. Lesch KP, Mössner R (1998) Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental and neurodgenerative disorders? Biol Psychiatry 44: 179-192
24. Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G (1997) Allelic functional variation of serotonin transporter expression is a susceptibility factor for late-onset Alzheimer's disease. Neuroreport 8: 683-686
25. Lucki I (1998) The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44: 151-162
26. Mann DMA, Yates PO (1986) Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol 5: 147-158
27. Mann DMA, Yates PO, Marcyniuk B, Ravindra CR (1985) Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res 29: 125-135
28. Mann DMA, Royston MC, Ravindra CR (1990) Some morphological observations on the brains of patients with Down's syndrome: their relationship to age and dementia. J Neurol Sci 99: 153
29. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardisation of the neuropathological assessment of Alzheimer's Disease. Neurol 41: 479-486
30. Nadel L, Epstein CJ (eds) (1992) Down Syndrome and Alzheimer disease. Wiley-Liss, New York (Prog Clin Biol Res 379)
31. Palmer AM, Stratmann GC, Procter AW, Bowen DM (1988) Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 23: 616-620
32. Procter AW, Francis PT, Chen CPLH, Chessel IP, Dijk S, Clarke NA, Webster MT, Bowen DM (1995) The neurochemical pathology of Alzheimer's disease. In: Allen SJ, Dawbarn D (eds) Neurobiolgy of Alzheimer disease. BIOS Scientific Publ, Oxford, pp 193-221
33. Reynolds GP, Godridge H (1985) Alzheimer-like brain monoamine deficits in adults with Down's syndrome. Lancet ii: 1368-1369
34. Risser D, Lubec G, Cairns N, Herrera-Marschitz M (1997) Excitatory amino acids and monoamines in parahippocampal gyrus and frontal cortical pole of adults with Down syndrome. Life Sci 60: 1231-1237
35. Rodriguez-Gomez JA, de la Roza C, Machado A, Cano J (1995) The effect of age on the monoamines of the hypothalamus. Mech Ageing Dev 77: 185-195
36. Singewald N, Kaehler S, Hemeida R, Philippu A (1997) Release of serotonin in the rat locus coeruleus: effects of cardiovascular, stressful and noxious stimuli. Eur J Neurosci 9: 556-562
37. Staley JK, Malison RT, Innis RB (1998) Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry 44: 534-549
38. Tierney MC, Fisher RH, Lewis AJ, Torzitto ML, Snow WG, Reid DW, Nieuwstraten P, Van Rooijen LAA, Derks HJGM, Van Wijk R, Bischop A (1998) The NINCDA-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease. Neurol 38: 359-364
39. Tu JB, Zellweger H (1965) Blood-serotonin deficiency in Down's syndrome. Lancet ii(7415): 715-716
40. Warren AC, Holroyd S, Folstein P (1989) Major depression in Down's syndrome. Br J Psychiatry 155: 202-207
41. Weise P, Koch R, Shaw KNF, Rosenfeld MJ (1974) The use of 5-HTP in the treatment of Down's syndrome. Pediatr 54: 165-167
42. Wisniewski KE, Kida E (1994) Abnormal neurogenesis and synaptogenesis in Down syndrome brain. Dev Brain Dysfunct 7: 289-301
43. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down syndrome. Ann Neurol 17: 278-282
44. Yates CM, Simpson J, Maloney AFJ, Gordon A, Reid AH (1980) Alzheimer-like cholinergic deficiency in Down syndrome. Lancet Nov 1st: 979
45. Yates CM, Simpson J, Gordon A, Maloney AFJ, Allison Y, Ritchie IM, Urquhart A (1983) Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280: 119-126
46. Yates CM, Simpson J, Gordon A (1986) Regional brain 5-hydroxytryptamine levels are reduced in senile Down's syndrome as in Alzheimer's disease. Neurosci Lett 65: 189-192